The p210 bcr-abl and p190 bcr-abl fusion proteins, respectively responsible for chronic myelogenous leukemia and acute lymphoblastic leukemia, present deregulated tyrosine kinase activity and abnormal localization. The Dbl homology domain of Bcr, activating Rho GTPases, is present in p210 bcr-abl , but absent in p190 bcr-abl . We investigated the interaction of Bcr-Abl chimeras and Rho proteins by coimmunoprecipitation, pull-down experiments and GEF activity measurement. RhoA, Rac1 and Cdc42 interact in vivo with p210 bcr-abl only. Moreover, the three types of GTPases are activated in vitro and in vivo by p210 bcr-abl . Nevertheless, Rac1 and Cdc42, but not RhoA, are activated by p190 bcr-abl in vitro and in vivo. Part of this GEF activity of p190 bcr-abl is probably attributable to p95 vav , which is complexed with both p190 bcr-abl and p210 bcr-abl in an activated form. p160 bcr , also in complex with Bcr-Abl, presents no GEF activity in p190 bcr-abl -expressing cells. These results suggest that differential activation of Rho proteins should play a major role in BcrAbl-induced leukemogenesis.
Introduction
Bcr-Abl is a chimeric oncogene generated by a reciprocal translocation between chromosomes 9 and 22 (Philadelphia chromosome, Ph þ ) that leads to the fusion of the 5 0 region of the bcr gene with the 3 0 region of the abl gene. Bcr is a multidomain cytosolic protein whose function in signal transduction has not yet been precisely defined. Bcr is composed of an oligomerization N-terminal domain, a serine kinase domain, a DH/PH domain specific for RhoA and Cdc42 and a C-terminal GAP domain active on Rac. The only function attributed to Bcr, the deactivation of neutrophil NADPH oxidase, relies on this latter domain (Voncken et al., 1995) . Abl is a nonreceptor tyrosine kinase that contains, in addition to other Src family proteins, a long C-terminal domain regulating its localization and consisting of several nuclear localization signals, a nuclear export signal, a DNA binding domain and a C-terminal F-actin binding domain (Van Etten, 1999) . Different types of chimeras comprising varying regions of Bcr and the greater part of Abl are found in several hematological diseases. Among them, p210 bcr-abl is the most frequent and responsible for chronic myelogenous leukemia (CML) (Daley et al., 1990) . Less frequent, p190 bcr-abl is associated with acute lymphoid leukemia (ALL) (Clark et al., 1988) . Both proteins exhibit enhanced and constitutive tyrosine kinase activity (Lugo et al., 1990; Ilaria and Van Etten, 1996) . Transformation by p210 bcr-abl is a complex mechanism, implicating enhanced proliferation and inhibition of apoptosis, but conserved differentiation. In this respect, the chronic phase cells cannot be characterized as fully transformed. In the absence of treatment, a fatal acute phase follows after 3-5 years, which can take different forms (myeloid, erythroid or even lymphoid). In contrast, p190 bcr-abl induces an immediately acute disease with undifferentiated blasts and inhibition of normal hematopoiesis. Interestingly, CML is associated with modifications of the actin cytoskeleton. Bcr-Abl, unlike c-Abl, is preferentially associated with F-actin , and its distribution changes in migrating cells (Skourides et al., 1999) . In fact, many substrates of Bcr-Abl are focal adhesion proteins such as paxillin, vinculin, talin and FAK (Salgia et al., 1995) .
The small GTPases of the Rho family (i.e. RhoA, Rac1 and Cdc42) are known regulators of the actin cytoskeleton (Tapon and Hall, 1997) . In addition to this action, they modulate apoptosis (Nishida et al., 1999) , proliferation (Olson et al., 1998) and myeloid differentiation (Ohguchi et al., 1997 ; for a review, see Zohn et al., 1998) . Interestingly, the isolated recombinant Dbl-homology domain (DH) of Bcr is an activator of Rho GTPases (Chuang et al., 1995) . It should be noted that the only difference between p190 bcr-abl and p210 bcr-abl resides in the absence of this DH domain in p190. Neither p190 bcr-abl nor p210 bcr-abl possess the RacGAP domain. Overexpression of Bcr in fibroblasts expressing p190 bcr-abl diminishes the latter's transformation potential (Wu et al., 1999) , which implies that some Bcr activities may regulate Bcr-Abl oncogenicity. Different substrates or partners of p210 bcr-abl are known modulators of Rho activity, as p190 rhoGAP (Druker et al., 1992; Cheng et al., 1995) . Moreover, Bcr-Abl phosphorylates p95
vav (Matsuguchi et al., 1995) . Vav, a GTP exchange factor (GEF) for Rac activated by tyrosine phosphorylation (Crespo et al., 1996) has been shown to be active toward Rac in Bcr-Abl-transformed cells (Skorski et al., 1998) . Vav may also activate Cdc42 (Olson et al., 1996; Han et al., 1997) . Finally, PI 3-kinase activity is enhanced by Bcr-Abl (Skorski et al., 1995) leading to an antiapoptotic pathway necessary for the survival of Ph þ cells (Skorski et al., 1997) . Among Rho family members, at least Rac is activated directly by PI 3-kinase products (Missy et al., 1998) .
On the basis of these elements, it seems likely that for proliferative, antiapoptotic and motility pathways, BcrAbl transduces signals through Rho proteins. We have thus decided to study the relations between Bcr-Abl and Rho proteins.
Here we show for the first time a difference between the pathways used by p190 bcr-abl and p210 bcr-abl . In contrast to p190 bcr-abl , p210
bcr-abl binds to small GTPases of the Rho family both in vitro and in vivo. The immunoprecipitated p210
bcr-abl complex activates RhoA, Rac1 and Cdc42, whereas the immunoprecipitated p190 bcr-abl complex, despite the absence of a DH domain in p190, is able to activate Rac1 and Cdc42 but not RhoA. Vav can form a complex with both forms of Bcr-Abl and may be responsible for the GEF activity of p190 bcr-abl . This differential activation of RhoA and Rac1/Cdc42 by p210 bcr-abl and p190 bcr-abl should have implications in the disease phenotype observed in each case.
Results

Coimmunoprecipitation of Rho proteins with p210 bcr-abl
In order to show a putative interaction between RhoA, Rac1 or Cdc42 and p210 bcr-abl , we first performed immunoprecipitation experiments. We used 8E9 monoclonal anti-Abl antibody to purify Abl and Bcr-Abl complexes from Ba/F3wt, Ba/F3p190 and Ba/F3p210 cells. As expected, in Ba/F3wt cells, only cAbl (145 kDa) was immunoprecipitated (Figure 1) . Immunostaining of the Western blot with anti-RhoA, anti-Rac1 or anti-Cdc42 antibodies showed no associated Rho GTPase in c-Abl complexes. In Ba/F3p190 cells, both p145 abl and p190 bcr-abl were precipitated. Neither RhoA, Rac1 nor Cdc42 was present in a complex with p190 bcr-abl in Ba/F3p190 cells. In contrast, in Ba/F3p210 cells, these GTPases were found associated in a complex with p210 bcr-abl . In all, 9.1% of total RhoA, 7.9% of total Rac1 and 7.0% of total Cdc42 were found associated with p210 bcr-abl .
GDP-and GTP-bound Rho proteins bind p190
bcr-abl and p210 bcr-abl differentially in vitro A characteristic of small GTPases is to bind in vitro to their GEFs in a GDP-bound or in a nucleotide-free state. In contrast, they bind to their effectors only in a GTP-bound form. To determine which form of Rho proteins bind Bcr-Abl, we have performed pull-down experiments using RhoA, Rac1 and Cdc42 as GST fusion proteins bound to glutathione-sepharose beads and preloaded with GDPbS or GTPgS, or nucleotidefree ( Figure 2 ). The GST protein alone retained no protein revealed by 8E9 antibody from any cell type tested. Interestingly, only p210 bcr-abl was retained on glutathione-sepharose beads carrying RhoA, Rac1 or Cdc42 in the GTP-bound form. Similarly, in the GDPbound and the nucleotide-free forms, p210 bcr-abl was retained by each Rho family GTPase. In contrast, p190
bcr-abl associated with Rac1 and Cdc42 in their nucleotide-free and GDP-bound forms, but was unable to bind to RhoA. In vitro, p210 bcr-abl forms a direct or indirect complex with the GTP-bound and the GDPbound forms of RhoA, Rac1 and Cdc42. In contrast, p190 bcr-abl binds directly or indirectly only to the GDPbound forms of Rac1 and Cdc42, which is a characteristic of GEFs. As p190 bcr-abl possesses no DH domain, this characteristic should be carried by one or more protein partners of p190 bcr-abl . The isolated DH domain of Bcr expressed as a GSTfusion protein shows a GEF activity preferentially toward Cdc42 and RhoA (Chuang et al., 1995) . In contrast, it activates Rac1 weakly. It should be noted that these experiments were done with a DH domain coupled with the N-terminal half of the adjacent PH domain. Thus, it is possible that this truncated PH domain was in part or totally inactive, and the activity observed may be different in vivo (Aghazadeh et al., 2000; Das et al., 2000) . Furthermore, p190 bcr-abl has no DH domain and should not be able to activate any of the Rho family GTPase. To investigate this activity, we performed anti-Abl immunoprecipitations from Ba/F3wt, Ba/F3p190 and Ba/F3p210 cells, and tested these immunoprecipitates for GEF activity toward Rho family GTPases (Figure 3 ). Cdc42 and Rac1 were activated by both p190 bcr-abl and p210 bcr-abl immunoprecipitates. In contrast, RhoA was activated only by p210 bcr-abl immunoprecipitates, and p190 bcr-abl immunoprecipitates had no GEF activity toward RhoA. Despite the lack of a DH domain, immunoprecipitated p190 bcr-abl was able to activate Cdc42 and Rac1. As a control, immunoprecipitated Vav from Ba/F3p190 or Ba/F3p210, which has been shown to be activated by Bcr-Abl (Matsuguchi et al., 1995) , presents a lower exchange rate than p190 or p210 immunoprecipitates toward Rac1.
Characterization of DH domain-containing molecular partners of Bcr-Abl in Ba/F3 cells
The GEF activity observed with anti-Abl immunoprecipitates from Ba/F3p190 cells is obviously not due to p190 bcr-abl itself, since no DH domain is present in its structure. Several reports show that in different cell types other DH domain-containing proteins interact with Bcr-Abl (Puil et al., 1994 , Matsuguchi et al., 1995 . The presence of an oligomerization domain at the N-terminus of Bcr allows the tetramerization of Bcr-Abl . It is possible that heterotetramers between Bcr-Abl and Bcr exist. Campbell et al. (1990) have shown that in a strain of K562 cells containing both p210
bcr-abl and p190
bcr-abl , p160 bcr is complexed with Bcr-Abl. To assess this possibility in our cell line, we performed immunoprecipitations with anti-Abl antibody (8E9) in Ba/F3p190 and Ba/F3p210 cells. P160 bcr forms a complex with both p190 bcr-abl and p210 bcr-abl , as revealed by anti-Bcr antibody on the Western blot ( Figure 4 ). p95 vav has been recently characterized as a GEF for Rac1 and Cdc42 (Han et al., 1997) . It is activated, Figure 2 Pull-down experiments with Rho GTPases as baits. GSH-sepharose-bound GST-Rho GTPases (2 mg) were preloaded with GTPgS, GDPbS or emptied by EDTA as described in Materials and methods. They were incubated with 1 ml of cell lysate corresponding to 2 Â 10 6 Ba/F3wt, Ba/F3p190 or Ba/F3p210 cells. Bead-bound complexes were loaded onto a 8% SDS-PAGE apparatus followed by Western blotting. The presence of Bcr-Abl was revealed using anti-Abl (8E9) antibody. Total cell lysates (20 mg of protein) are migrated in parallel for control among other mechanisms, by tyrosine phosphorylation (Aghazadeh et al., 2000) . Interestingly, Matsuguchi et al. (1995) showed that in 32Dcl3 cells expressing a p210 bcr-abl temperature-sensitive mutant for kinase activity, Vav was phosphorylated on tyrosine, only at the permissive temperature. Furthermore, Skorski et al. (1998) performed GEF assays on Rac1 with immunoprecipitated Vav from 32Dcl3 cells expressing p210 bcr-abl , and showed that Vav is able to activate Rac1 in these cells. To explore the role of Vav in the GEF activities observed in the previous experiments (Figure 3 ), we performed anti-Abl immunoprecipitations from Ba/F3wt, Ba/F3p190 and Ba/F3p210 cells ( Figure 4 ). We show that p95 vav is present complexed with p145 abl , p190
bcr-abl and p210 bcr-abl . Immunostaining with PY20 antibody reveals a band corresponding to the Mr of Vav only in p190 and p210 immunoprecipitates. Together with previous reports (Matsuguchi et al., 1995) , these results suggest that Vav is in an activated form not only in Ba/F3p210 cells, but also in Ba/F3p190 cells.
Inactivation of p160
bcr in p190 bcr-abl -expressing cells
Vav is known to activate Rac1 and Cdc42, but to have a weak activity toward RhoA (Han et al., 1997). In Immunoprecipitates were loaded onto a 8% SDS-PAGE apparatus followed by Western blotting. The presence of Abl, Bcr-Abl, Bcr and Vav was revealed using anti-Abl (8E9) (upper), anti-Bcr (G6) (middle) or anti-Vav (lower) antibodies, and tyrosine phosphorylation of Vav was revealed using PY20 (lower) antibody.
Results are representative of four independent experiments
Rho GTPases and Bcr-Abl T Harnois et al contrast, Bcr shows GEF activity toward Cdc42 and RhoA, but a weak activity toward Rac1 (Chuang et al., 1995) . If Bcr is complexed with both p190 bcr-abl and p210 bcr-abl , why might p190 bcr-abl not be able to activate RhoA? To clarify this point, we performed anti-Bcr immunoprecipitation of Ba/F3wt and Ba/F3p190 cells ( Figure 5 ). The respective amounts of p160 bcr immunoprecipitated from each cell type was almost the same as determined by densitometric analysis of the band revealed by anti-Bcr antibody. Using these anti-Bcr immunoprecipitates from Ba/F3wt and Ba/F3p190 cells, we then performed GEF activity measurements toward RhoA. In parallel, anti-Abl immunoprecipitates from Ba/F3wt and Ba/F3p190 cells were also performed and tested for GEF activity toward RhoA ( Figure 5 ). As previously shown in Figure 3 , no GEF activity toward RhoA can be associated with anti-Abl immunoprecipitates, either from Ba/F3wt cells or from Ba/F3p190 cells. In contrast, anti-Bcr immunoprecipitates from Ba/F3wt cells showed a classic GEF activity toward RhoA, in agreement with the results obtained by Chuang et al. (1995) . Anti-Bcr immunoprecipitates from Ba/F3p190 cells showed no GEF activity toward RhoA. The same experiment was done in Ba/F3p210, but as expected no difference in GEF activity toward RhoA was seen between anti-Abl and anti-Bcr immunoprecipitates (data not shown).
Localization of Rho proteins in Ba/F3 cells
We have shown that p210 bcr-abl and p190 bcr-abl present a differential GEF activity toward Rho proteins. To explore this activity in our cell lines, we performed confocal microscopy experiments in order to visualize the localization of Rho proteins. It has been demonstrated that Rho proteins, when activated, are translocated from a cytosolic compartment to a submembrane localization (Adamson et al., 1992) . In Ba/F3wt cells, RhoA, Rac1 and Cdc42 are cytosolic (Figure 6a-c) . Interestingly, a large amount of GTPase was concentrated in a perinuclear area. In Ba/F3p190 cells, RhoA is also cytosolic (Figure 6d ). Nevertheless, in these cells, Rac1 and Cdc42 are in part localized in a membrane or submembrane compartment (Figure 6e, f) . This differential localization indicates that RhoA is not activated in Ba/F3p190 cells, but that Rac1 and Cdc42 are partly activated. In contrast to Ba/F3p190 cells, in Ba/F3p210 cells RhoA, Rac1 and Cdc42 show a partial membrane or submembrane localization, suggesting that they are in an activated form (Figure 7 g-i) .
Activation state of Rho proteins in different Ba/F3 cell types
A characteristic of Rho GTPases is to bind to their effectors in an activated GTP-bound form. This property was used to measure the relative amount of GTP-bound GTPases contained in a cell by pull-down experiments with the GTPase binding (GB) domain of PAK (PAK-CD) or Rhotekin (C21) (Sander et al., 1998) . Equal quantities (10 7 cells) of untreated Ba/F3wt, Ba/F3p190 or Ba/F3p210 cells were lysed as described in Materials and methods, and the lysates were incubated with purified GB domains (PAK-CD or C21) fused with GST and immobilized on GSH-sepharose beads. Bound proteins, corresponding to GTP-bound forms of the GTPases, were separated on SDS-PAGE and visualized by immunoblotting analysis using anti-RhoA, anti-Rac1 or anti Cdc42 antibodies (Figure 7) . The major part of RhoA was in inactivated form in Ba/F3wt and Ba/F3p190 cells. In contrast, a significant proportion of RhoA was in the activated GTP-bound form in Ba/F3p210 cells. The activated forms of Rac1 and Cdc42 were significantly more abundant in Ba/F3p190 and Ba/F3p210 cells, as compared to Ba/F3wt cells. These experiments show that RhoA is activated only in Ba/F3p210 cells, but that Rac1 and Cdc42 are activated in both Ba/F3p190 and Ba/F3p210 cells.
Discussion
In this study, we have examined the involvement of small GTP-binding proteins of the Rho family in the . We have also shown that p210 bcr-abl is able to activate RhoA, Rac1 and Cdc42, while p190 bcr-abl activates only Rac1 and Cdc42. Ba/F3 cell lines have been widely used in different laboratories to characterize Bcr-Abl-related events. These IL3-dependent hematopoietic cell lines are transformed by each Bcr-Abl chimera (i.e. p190, p210 and p230) (Daley and Baltimore, 1988; Li et al., 1999; Quackenbush et al., 2000) .
The signaling of Bcr-Abl through actin cytoskeleton disorganization has been intensely studied in recent years (Verfaillie et al., 1995; Bazzoni et al., 1996; Salgia et al., 1997) , but the involvement of Rho GTPases in these pathways has been investigated only indirectly (Skorski et al., 1998) . We established that a complex exists between Rho GTPases and p210 bcr-abl , but not between Rho GTPases and p190 bcr-abl . This association was shown by coimmunoprecipitation assays, using anti-Abl antibody to immunoprecipitate Bcr-Abl. It should be noted that when an anti-RhoA antibody was used, only p210 bcr-abl was coimmunoprecipitated (data not shown). The most likely hypothesis to explain this association would be the presence of a DH domain on p210 that is absent in p190. Nevertheless, no data in the literature support the idea that small G proteins form stable complexes with their activators, whereas many reports show stable association with effectors in the GTP-bound state (Eda et al., 2001; Hansen and Nelson, 2001; Rudolph et al., 2001) . Pull-down assays, using Rho GTPases in GDP, GTP and nucleotide-free forms as baits, show that p210 bcr-abl is able to bind in vitro to both active and inactive RhoA, Rac1 and Cdc42. On the other hand, p190 bcr-abl , which does not coimmunoprecipitate with Rho GTPases in a whole cell system, binds only with the GDP and nucleotide-free forms of Rac1 and Cdc42 in a cell-free system. One can then postulate that the complex revealed by immunoprecipitation arises through the GTP-bound form of GTPases.
Confocal microscopy analysis of Rho family protein localization pointed out the differential activation of Rho GTPases in Ba/F3p190 and Ba/F3p210. In Ba/F3wt cells, Rho GTPases are cytosolic and therefore not activated (Adamson et al., 1992) . In Ba/F3p190 cells, Rac1 and Cdc42 are in part translocated to the plasma membrane, a localization characteristic of activated GTP-bound forms of these GTPases. However, RhoA is not translocated to the membrane and persists as a cytosolic unactivated protein. In contrast, in Ba/F3p210 cells, all three Rho GTPases display a partial redistribution to the plasma membrane. These observations are confirmed by pull-down experiments using Rho GTPase-binding domain of effectors (Rhotekin or PAK) as bait to trap GTP-bound forms of these proteins. A significant part (3.6 -6.4%) of Rac1 and Cdc42 is in activated form in both Ba/F3p190 and Ba/F3p210 cells. In contrast, a part of RhoA (4.5%) is in activated form only in Ba/F3p210 cells. In Ba/F3wt cells, the major part (499%) of RhoA, Rac1 and Cdc42 is in the GDP-bound inactive form. This activation of Rho GTPases in Ba/F3p190 and Ba/F3p210 cells is obviously due to the presence of Bcr-Abl chimeras in these cells. In fact, Bcr-Abl chimeras form multiprotein complexes with their molecular partners that may contain GEF activity toward Rho GTPases. In complete agreement with the above results, immunoprecipitated p210 bcr-abl complexes showed a GEF activity toward recombinant RhoA, Rac1 and Cdc42. Similarly, only recombinant Rac1 and Cdc42 were activated by immunoprecipitated p190 bcr-abl complexes, and no GEF activity toward RhoA could be measured. The DH domain of Bcr is absent in p190 bcr-abl , and the activation of Rac1 and Cdc42 observed in this case must thus be indirect. Our results show that p95 vav , a GEF for Rac1 and Cdc42 precisely activated by Bcr-Abl (Matsuguchi et al., 1995) , is present in a stable complex with p190 bcr-abl and p210 bcr-ab1 . Vav, phosphorylated by Bcr-Abl may be responsible for this latter activity. The activation of Rac1 by p210 bcr-abl should also be indirect. A recent report confirms this hypothesis, showing that Vav, through its SH2 domain, is in complex with Bcr-Abl, and is responsible of the Rac1 activation induced by Bcr-Abl (Bassermann et al., 2002) . Also present in both complexes, p160 bcr is inactivated. Our results show that immunoprecipitated p160 bcr from Ba/F3wt cells has GEF activity toward RhoA, but that immunoprecipitated p160 bcr from Ba/F3p190 cells has no more or at least a largely inhibited activity. In Ba/F3p210 cells, we were not able to differentiate immunoprecipitated Bcr GEF activity from the one of immunoprecipitated p210 bcr-abl by anti-Abl antibody, since a similar amount of p210 bcr-abl was present in both preparations. Interestingly, the exchange rate of GDP activated by immunoprecipitated Bcr-Abl is rapid when compared with results obtained in vitro by Chuang et al. (1995) . We measured the exchange activated by anti-Vav immunoprecipitates toward Rac1 (Figure 3b ). Immunoprecipitated Bcr-Abl is more efficient than immunoprecipitated Vav from the same cells. A similar observation was published by Lippe´et al. (2001) concerning Rab5, who showed that the complex of Rabex-5 (GEF for Rab5) with Rabaptin-5 (effector of Rab-5) was more effective than Rabex-5 alone for GDP-GTP exchange. The presence of different effectors could also potentiate the exchange rate of GDP toward ARF3 (Zhu et al., 2000) . The presence of effectors in complex with Bcr-Abl is currently under experimentation.
Cdc42 and Rac1 are central regulators of cell motility (Nobes and Hall, 1999) , Cdc42 being required to Rho GTPases and Bcr-Abl T Harnois et al establish cell polarity and Rac1 to permit protrusive activity. RhoA is not required for cell movement, although a basal RhoA activity is necessary to maintain cell substrate adhesion. This proadherent effect of RhoA seems to counterbalance the effects of Rac1 and Cdc42, and at least Rac1 must inhibit RhoA to exert its activity toward myosin (Sander et al., 1999) . Apart from these cytoskeletal effects, Rho proteins act on other important pathways, such as apoptosis, proliferation and differentiation (for a review, see Zohn et al., 1998) . Again, Rac1/Cdc42 and RhoA effects can be distinguished. Rac1 is an important key in Ras transformation (Qiu et al., 1995; Burstein et al., 1998) , and mediates cell survival signals through PI3-kinase/Akt pathway activation (Nishida et al., 1999) . Cdc42 may have the same proproliferative and antiapoptotic activities as Rac1, because isolated inhibition of Rac1 in Bcr-Abl cells induces no change in apoptosis or proliferation status (Skorski et al., 1998) . In fact, like Rac1, Cdc42 activates both PI3-kinase and PAK, two regulators of these pathways (Tolias et al., 1995; Roig et al., 2000) . In contrast, RhoA is implicated in G1 control of Rafinduced proliferation (Olson et al., 1998) and most likely, through phospholipase D activation, promotes myeloid cell differentiation (Nakashima and Nozawa, 1999) .
To summarize, Rac1 and Cdc42 may act preferentially as coactivators of the oncogenicity of Bcr-Abl, whereas RhoA is expected to behave as a regulator; p190 bcr-abl , which is responsible for acute leukemia, activates Rac1 and Cdc42, but not RhoA, and this should contribute to the much more aggressive expression of the disease. On the other hand, p210
bcr-abl does not fully transform hematopoietic progenitors, terminal myeloid differentiation of Ph þ cells being achieved during the chronic phase of CML. In these cells, Rac1 and Cdc42 may contribute to Bcr-Abl-activated proliferation, cell survival and motility, but the concomitant activation of RhoA should permit the differentiation of progenitors and a less-aggressive phenotype. These hypothesis are to be validated, and it would be of interest to determine the activation status of Rho proteins on CML and ALL patient cells.
Materials and methods
Cells
The murine hematopoietic cell line Ba/F3 (Ba/F3wt) was cultured in RPMI 1640 (Gibco BRL) containing 10% fetal calf serum (FCS) (Valbiotech, France) and 10 ng/ml of rm-IL3 (generous gift of Eric Lelie`vre, INSERM E99-28, Angers, France) at 371C with 5% CO 2 . For stable transfection, retroviruses were produced by transfecting Phoenixampho cells (ATCC, Manassas, VA, USA and Garry Nolan, Stanford University Medical Center, CA, USA) with pGD vector containing the cDNAs of the different forms of Bcr-Abl (gift of George Daley, Whitehead Inst., Cambridge, MA, USA). The Bcr-Abl-expressing cell lines Ba/F3p210 and Ba/F3p190 were generated by infection with retrovirus supernatants as described (Daley and Baltimore, 1988; Pear et al., 1993) .
Antibodies
Antibodies against Abl: mouse monoclonal antibody 8E9 (Pharmingen) and rabbit polyclonal Ab-1 (Oncogene Research, Cambridge, MA, USA). Antibodies against Bcr: mouse monoclonal antibody G6 and rabbit polyclonal N-20 (Santa Cruz Biotechnology Inc., CA, USA). Other antibodies used were: anti-RhoA (26C4, mouse monoclonal, Santa Cruz Biotechnology Inc., CA, USA); anti-Rac (mouse monoclonal 23A8, Upstate Biotechnology, Lake Placid, NY, USA); antiCdc42 (P1-G rabbit polyclonal and B-8 mouse monoclonal, Santa Cruz Biotechnology Inc., CA, USA); anti-Vav (mouse monoclonal ascites, Upstate Biotechnology, Lake Placid, NY, USA); anti-Vav (H-111 rabbit polyclonal, Santa Cruz Biotechnology Inc., CA, USA); antiphosphotyrosine (PY20 mouse monoclonal, transduction Laboratories, Lexington KY, USA).
Secondary antibodies for immunofluorescence were obtained from Molecular Probes: Alexa488-conjugated goat anti-mouse IgG, Alexa488-conjugated goat anti-rabbit IgG. Secondary antibodies for Western blotting were obtained from Amersham Pharmacia Biotech: HRP-conjugated goat antimouse IgG and HRP-conjugated goat anti-rabbit IgG, or from Santa Cruz Biotechnology Inc., CA, USA: HRP-conjugated donkey anti-goat IgG.
Recombinant proteins
PGEX-2 T vectors containing the cDNAs of RhoA, Rac1 and Cdc42 were obtained from Allan Hall (University College London, UK). Recombinant proteins were prepared as glutathione S-transferase fusion proteins in Escherichia coli (BL21 strain), purified using glutathione-sepharose beads (Amersham Pharmacia Biotech), eluted with glutathione and used as GST-fusion proteins. The GST-PAK-CRIB domain and GST-Rhotekin-RBD (C21) were obtained as pGEX-2 T fusion genes (gift of JG Collard, Netherlands Cancer Institute, Amsterdam, NL, USA) and produced as described (Sander et al., 1998) .
Affinity binding assay
A total of 10 7 Ba/F3wt, Ba/F3p190 or Ba/F3p210 cells were washed twice in cold PBS and then lysed in 1 ml of lysis buffer (Tris HCl 50 mm pH 7.4,. NaCl 100 mm, MgCl 2 2 mm, 1% NP-40 (w/v), 10% glycerol, PMSF 1 mm, leupeptine 20 mm, aprotinine 0.8 mm, pepstatine 10 mm). Total amount of protein in each lysate was measured and corresponded to 2 mg/ml. Lysates were clarified by centrifugation at 15 000 g for 15 min at 41C and the supernatant was mixed into 50 ml of GST-fusion protein (C21: Rhotekin-Rho-binding-domain or PAK-CD: PAK-CRIB-domain) corresponding to 5 mg of protein bound to glutathione-sepharose beads. Incubation was conducted at 41C for 1 h. Bead-bound complexes were washed four times in lysis buffer, boiled in Lae¨mmli sample buffer and fractionated by a 13% SDS-PAGE, followed by Western blotting. For the C21 assay, the presence of RhoA was revealed using antiRhoA antibody. For the PAK-CD assay, the presence of Rac1 and Cdc42 was revealed using anti-Rac1 or anti-Cdc42 antibodies.
For GST-Rho proteins binding assays, 2 mg of GSHsepharose bead-bound GTPases were loaded with GDPbS, GTPgS or emptied by EDTA as described in Missy et al. (1998) . In all, 2 Â 10 6 Ba/F3wt, Ba/F3p190 or Ba/F3p210 cells were washed twice in cold PBS and then lysed in 200 ml of RIPA buffer (Tris-HCl 50 mm pH 7.4, NaCl 150 mm, EDTA 5 mm, MgCl 2 5 mm, 0.05% NP-40 (w/v), 1% sodium deoxycholate (w/v), 1% Triton X-100 (w/v), 0.1% SDS (w/v), PMSF 1 mm, leupeptine 20 mm, aprotinine 0.8 mm, pepstatine 10 mm). DNA and F-actin aggregates were disrupted by flushing several times through a syringe needle. Then 800 ml of NET buffer (Tris-HCl 50 mm pH 7.4, EDTA 5 mm, MgCl 2 5 mm, NaCl 150 mm, 0.05% NP-40, PMSF 1 mm, leupeptine 20 mm, aprotinine 0.8 mm, pepstatine 10 mm) were added and the lysate was clarified by centrifugation at 15 000 g for 15 min at 41C. The supernatant was mixed with preloaded (GDP or GTP) or nucleotide-free GTPases in the presence of 10 mm MgCl 2 . Incubation was carried out for 1 h at 41C. Bead-bound complexes were washed four times in NET buffer, boiled in Lae¨mmli sample buffer and fractionated by a 7% SDS-PAGE, followed by Western blotting. The revelation was made using anti-Abl antibody (8E9).
Immunoprecipitation
Cell lysates were obtained from 10 7 Ba/F3wt, Ba/F3p190 or Ba/F3p210 cells. Cells were washed twice in PBS and then lysed in 1 ml of RIPA buffer. DNA and F-actin aggregates were disrupted by flushing several times through a syringe needle. Then 4 ml of NET buffer was added and the lysate was clarified by centrifugation at 15 000 g for 15 min at 41C. A measure of 1 ml of the supernatant was incubated overnight with first antibody at 41C with continuous agitation. For anti-Abl immunoprecipitation, 1.6 mg of 8E9 antibody was used; for anti-Bcr immunoprecipitation, 2 mg of G6 antibody was used; for anti-Vav immunoprecipitation, 2 mg of H211 was used. To precipitate the immune complexes, an incubation with 30 ml of protein G-sepharose (100 mg/ml) or protein A-sepharose (Amersham-Pharmacia) was conducted for 1 h at 41C. Bead-bound complexes were washed four times with a cold lysis buffer containing 10 mm MgCl 2 . They were used for GTP-exchange assays or boiled in the Lae¨mmli sample buffer and loaded onto an SDS-PAGE apparatus. Lae¨mmli and Favre (1973) . Gels were stained with Coomassie brilliant blue R-250. For Western blots, proteins were transferred from gels to nitrocellulose membranes (0.20 mm pore) (Sartorius, Go¨ttingen, Germany) using a Miniprotean electroblotter (Biorad laboratories, Hercules, CA, USA). Immunoblots were washed three times in PBS containing 0.1% Tween-20 (PBS-Tween) and then probed overnight at 41C with antibody in PBS-Tween. Following three washes with PBS-Tween, membranes were incubated for 1 h at 41C with antimouse immunoglobulin (HRP-linked whole antibody from sheep) or antirabbit immunoglobulin (HRPlinked whole antibody from donkey) (Amersham-Pharmacia). The membranes were washed three times for 5 min per wash with PBS-Tween, and bound antibodies were detected using enhanced luminol and oxidizing reagent as specified by the manufacturer (ECL, AmershamPharmacia).
SDS-PAGE and immunoblots
SDS-PAGE was performed according to
Immunofluorescence and confocal microscopy
Ba/F3 cells were washed in PBS twice and resuspended at 10 6 cells per ml. Cell suspension (100 ml) was plated on a glass coverslip precoated with ECM-gel (Sigma) and cultured for 24 h. Coverslips were washed with TBS. Cells were fixed in 3% PFA for 10 min, washed with TBS, then permeabilized with a solution of PIPES 80 mm pH 6.4, MgCl 2 1 mm, EGTA 5 mm and 0.1% saponin for 2 min. For Cdc42 staining, after PFA, a second fixation in methanol at À201C was performed for 2 min. Cells were washed with TBS containing 2% BSA and coverslips were incubated on a parafilm with normal goat serum (10% in TBS) for 15 min at room temperature. Then, coverslips were incubated for 1 h with 20 ml)l of a mix of antibodies (1% anti-RhoA, 1/80 anti-Rac1 or 1% anti-Cdc42) made up in 2% NGS. Cells were washed twice for 5 min in 2% TBS-BSA, and then incubated for 1 h with secondary antibodies (1% anti-rabbit Alexa488 for Cdc42 or 1% anti-mouse Alexa488 for Rac1 and RhoA) and 1/200 TO-PRO-3 (Molecular Probes). Coverslips were washed three times in TBS-BSA 2%, and then mounted with Vectashield fluorescence medium H-1000 (Vector Lab. Inc., Burlingame, CA, USA). Immunolabeled samples were examined by confocal laser scanning microscopy using a Biorad MRC 1024 ES equipped with an argon-krypton gas laser and deconvoluted using the Imaris software (Bitplane). 7 cells, and GTP (1 mm final). The incubation was conducted with continuous agitation at 251C for 15 min. At the indicated times, 30 ml of aliquots were removed and added to 1 ml of ice-cold stop solution (Tris-HCl 25 mm pH 7.4, NaCl 100 mm, MgCl 2 30 mm, 2 mm DTT) and the content of the tube was filtered under vacuum onto a HA 0.45 mm nitrocellulose filter. The filter was washed five times with 1 ml of stop solution; then radioactivity fixed on the filter was quantified by liquid scintillation counting. The association of [ 35 S]GTPgS to the GDP-bound form of GST-GTPases was carried out according to Hoshino et al. (1999) , with slight modifications. In brief, 80 ml of protein-G-sepharose-bound complexes obtained with anti-Abl antibody on 10 7 cells was mixed with 40 pmol of GDP-bound GTPases in 300 ml of 50 mm Tris-HCl pH 8.0, 1 mm DTT, 10 mm MgCl 2 and 2.9 mm EDTA, and 3 ml of 100 mm GTPgS containing GTPg[ 35 S]. The incubation was conducted with continuous agitation at 251C for 15 min. At the indicated times, 35 ml aliquots were removed and added to 1 ml of icecold stop solution and the content of the tube was filtered under vacuum onto an HA 0.45 mm nitrocellulose filter. The filter was washed five times with 1 ml of stop solution; then radioactivity fixed on the filter was quantified by liquid scintillation counting. Results are expressed as mol of GTP bound per mol of GTPase.
GDP releasing and GTP binding assays
